Oral Delta-9-Tetrahydrocannabinol (THC) Increases Parasympathetic Activity and Supraspinal Conditioned Pain Modulation in Chronic Neuropathic Pain Male Patients: A Crossover, Double-Blind, Placebo-Controlled Trial

被引:1
|
作者
Weizman, Libat [1 ]
Sharon, Haggai [1 ,2 ,3 ,4 ]
Dayan, Lior [4 ]
Espaniol, Joumana [5 ,6 ]
Brill, Silviu [4 ]
Nahman-Averbuch, Hadas [7 ]
Hendler, Talma [1 ,2 ,3 ,8 ]
Jacob, Giris [2 ,3 ,5 ,6 ]
机构
[1] Tel Aviv Sourasky Med Ctr, Wohl Inst Adv Imaging, Sagol Brain Inst, Tel Aviv, Israel
[2] Tel Aviv Univ, Sagol Sch Neurosci, Tel Aviv, Israel
[3] Tel Aviv Univ, Sch Med, Tel Aviv, Israel
[4] Tel Aviv Sourasky Med Ctr, Inst Pain Med, Dept Anesthesiol & Crit Care Med, Tel Aviv, Israel
[5] Tel Aviv Sourasky Med Ctr, Dept Internal Med F, Tel Aviv, Israel
[6] Tel Aviv Sourasky Med Ctr, Recanati Auton Dysfunct Ctr, Tel Aviv, Israel
[7] Washington Univ St Louis, Sch Med, Pain Ctr, Dept Anesthesiol,Div Clin & Translat Res, St Louis, MO USA
[8] Tel Aviv Univ, Sch Psychol Sci, Tel Aviv, Israel
关键词
HEART-RATE-VARIABILITY; DIRECT-CURRENT STIMULATION; BRAIN; MECHANISMS; PATHWAYS; SYSTEMS; STRESS; ADULTS;
D O I
10.1007/s40263-024-01085-0
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Disordered autonomic nervous system regulation and supraspinal pain inhibition have been repeatedly described in chronic pain. We aimed to explore the effects of delta-9-tetrahydrocannabinol (THC), an emerging treatment option, on autonomic nervous system and central pain modulation measures in patients with chronic pain. Methods: Twelve male patients with chronic radicular neuropathic pain participated in a randomized, double-blind, crossover, placebo-controlled, single-administration trial. Low/high frequency (LF/HF) heart rate variability (HRV) ratio and conditioned pain modulation (CPM) response were measured and resting-state functional magnetic resonance imaging (MRI) was performed at baseline and after sublingual administration of either 0.2 mg/kg oral THC or placebo. Results: THC significantly reduced the LF/HF ratio compared with placebo (interaction effect F(1,11) = 20.5; p < 0.005) and significantly improved CPM responses (interaction effect F(1,9) = 5.2; p = 0.048). The THC-induced reduction in LF/HF ratio correlated with increased functional connectivity between the rostral ventrolateral medulla and the dorsolateral prefrontal cortex [T(10) = 6.4, cluster p-FDR < 0.005]. Conclusions: THC shifts the autonomic balance towards increased parasympathetic tone and improves inhibitory pain mechanisms in chronic pain. The increase in vagal tone correlates with connectivity changes in higher-order regulatory brain regions, suggesting THC exerts top-down effects. These changes may reflect a normalizing effect of THC on multiple domains of supraspinal pain dysregulation.
引用
收藏
页码:375 / 385
页数:11
相关论文
共 50 条
  • [31] Trachyspermum ammi 10 % topical cream versus placebo on neuropathic pain, a randomized, double-blind, placebo-controlled trial
    Peyman Petramfar
    Mahmoodreza Moein
    Soliman Mohammadi Samani
    Sayed Hamidreza Tabatabaei
    Mohammad M. Zarshenas
    Neurological Sciences, 2016, 37 : 1449 - 1455
  • [32] Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)
    Janet Hardy
    Alison Haywood
    Gauri Gogna
    Jennifer Martin
    Patsy Yates
    Ristan Greer
    Phillip Good
    Trials, 21
  • [33] A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF ESZOPICLONE FOR THE TREATMENT OF INSOMNIA IN PATIENTS WITH CHRONIC LOW BACK PAIN
    Krystal, A. D.
    Preud'homme, X. A.
    Goforth, H. W.
    SLEEP, 2012, 35 : A216 - A216
  • [34] A Randomized, Double-Blind, Placebo-Controlled Trial of Eszopiclone for the Treatment of Insomnia in Patients with Chronic Low Back Pain
    Goforth, Harold W.
    Preud'homme, Xavier A.
    Krystal, Andrew D.
    SLEEP, 2014, 37 (06) : 1053 - 1060
  • [35] Chinese Medicinal Formula (MHGWT) for Relieving Diabetic Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Trial
    Tsai, Chia-I
    Li, Tsai-Chung
    Chang, Ming-Hong
    Lin, Shih-Yi
    Lee, I-Te
    Lee, Cheng-Hung
    Wang, Tzu-Yuan
    Su, Yi-Chang
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2013, 2013
  • [36] Topical 2% amitriptyline and 1% ketamine in neuropathic pain syndromes - A randomized, double-blind, placebo-controlled trial
    Lynch, ME
    Clark, AJ
    Sawynok, J
    Sullivan, MJL
    ANESTHESIOLOGY, 2005, 103 (01) : 140 - 146
  • [37] Sativex successfully treats neuropathic pain characterised by allodynia: A randomised, double-blind, placebo-controlled clinical trial
    Nurmikko, Turo J.
    Serpell, Mick G.
    Hoggart, Barbara
    Toomey, Peter J.
    Morlion, Bart J.
    Haines, Derek
    PAIN, 2007, 133 (1-3) : 210 - 220
  • [38] The effect of lacosamide in peripheral neuropathic pain: A randomized, double-blind, placebo-controlled, phenotype-stratified trial
    Carmland, Malin Erika
    Kreutzfeldt, Melissa Dall
    Holbech, Jakob Vormstrup
    Brask-Thomsen, Peter Kolind
    Kroigard, Thomas
    Hansen, Peter Norregaard
    Tankisi, Hatice
    Jensen, Troels Staehelin
    Bach, Flemming Winther
    Sindrup, Soren Hein
    Finnerup, Nanna Brix
    EUROPEAN JOURNAL OF PAIN, 2023, : 105 - 119
  • [39] A randomised, double-blind, placebo-controlled trial of duloxetine for the treatment of central neuropathic pain associated with multiple sclerosis
    Vollmer, T.
    Robinson, M.
    Risser, R.
    Malcolm, S. K.
    Carlson, J.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S476 - S477
  • [40] Duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: A randomized, double-blind, placebo-controlled trial
    Vranken, J. H.
    Hollmann, M. W.
    van der Vegt, M. H.
    Kruis, M. R.
    Heesen, M.
    Vos, K.
    Pijl, A. J.
    Dijkgraaf, M. G. W.
    PAIN, 2011, 152 (02) : 267 - 273